Status:
ACTIVE_NOT_RECRUITING
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
Lead Sponsor:
University Hospital Birmingham
Collaborating Sponsors:
University of Birmingham
Conditions:
Atrial Fibrillation
Recurrence
Eligibility:
All Genders
18+ years
Brief Summary
Atrial Fibrillation (AF) is the most common abnormal heart rhythm(arrhythmia) affecting about one in 40 people in England. Patients with AF often have symptoms ranging from palpitations and breathless...
Detailed Description
Patients meeting the inclusion criteria waiting for atrial fibrillation (AF) ablation in Queen Elizabeth Hospital of Birmingham will be invited for the study. The investigators aim to recruit 30 pati...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with symptomatic paroxysmal or persistent Atrial Fibrillation on the waiting list for AF ablation at Queen Elizabeth Hospital Birmingham who
- are more than 18 and less than 80 of age,
- have paroxysmal or persistent AF,
- symptomatic: palpitations, shortness of breath, feeling of an irregular pulse or pause in heart activity, light-headedness, or dizziness) despite pharmacological anti-arrhythmic agents (or inability to take medications) therefore making them eligible for ablation therapy,
- are above BMI- 30 kg/m2
- Exclusion criteria:
- Any one of the followings;
- unable to undergo CMR,
- Patients who are currently treated with a weight losing drug - including Orlistat, GLP-1 analogues or have had/or awaiting bariatric surgery,
- Type 1 diabetes,
- Type 2 diabetes on DPP-IV inhibitor or insulin: as blood sugar will need close monitoring on GLP-1 and insulin,
- Patients with decompensated liver disease, end-stage renal disease or eGFR \<30, NYHA class III/IV heart failure or active malignancy,
- Any malignancy within the last 2 years except skin malignancies,
- Pregnancy,
- Patients with a history of thyroid cancer or pancreatitis,
- Patients with a needle phobia.
Exclusion
Key Trial Info
Start Date :
April 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2026
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT05221229
Start Date
April 17 2022
End Date
June 1 2026
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom, B15 2GW